FY2025 · ended Dec 31, 2025 · Revenue $86.55M, -8.1% YoY · Filed Mar 13, 2026
Harvard Bioscience, Inc. (HBIO) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $86.5 million and a net loss of $56.7 million. Free cash flow was $5.5 million. As of Jun 30, 2026 it held $6.5 million in cash and investments and $44.2 million in total debt.
Revenue (TTM)
$87.81M
-1.1% vs year-ago TTM
Net income (TTM)
$-10.41M
+81.9% vs year-ago TTM
Operating cash flow (TTM)
$651,000
-90.2% vs year-ago TTM
Free cash flow (TTM)
$-1.12M
-123.1% vs year-ago TTM
EPS (TTM)
$-0.23
+90.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
44.72M
+1.5% vs prior year
Net cash
$-37.70M
as of Jun 30, 2026
Operating margin
-0.3%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- HBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Holliston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1123494
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $86.5M | $94.1M | $112.2M | $113.3M | $118.9M |
| Operating income | -$48.6M | -$6.2M | $1.9M | -$6.9M | $2.1M |
| Net income | -$56.7M | -$12.4M | -$3.4M | -$9.5M | -$288,000 |
| Diluted EPS | -$1.28 | -$0.28 | -$0.08 | — | — |
| Operating cash flow | $6.7M | $1.4M | $14.0M | $1.2M | $1.3M |
| Free cash flow | $5.5M | -$1.2M | $12.2M | -$438,000 | $67,000 |
| Total assets | $80.1M | $126.6M | $137.4M | $145.4M | $162.3M |
| Total liabilities | $66.3M | $63.3M | $64.3M | $73.1M | $78.9M |
| Stockholders' equity | $13.7M | $63.3M | $73.1M | $72.2M | $83.4M |
| Cash and investments | $8.6M | $4.1M | $4.3M | $4.5M | $7.8M |
| Total debt | $44.3M | $44.5M | $43.1M | $54.5M | $57.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 2, 2026 | Jun 2, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
All 1000 Harvard Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.